Theriva Biologics, Inc. recently disclosed the outcomes of a Type D meeting with the U.S. Food and Drug Administration (FDA), outlining details regarding the design of a Phase 3 clinical study ...
Shares of European Opportunities Trust plc (LON:JEO – Get Free Report) were down 2.4% during mid-day trading on Friday . The stock traded as low as GBX 841.44 ($10.73) and last traded at GBX 843 ($10.
Phase 2 trial of petosemtamab in combination with standard chemotherapy in 2L metastatic colorectal cancer (mCRC) enrolling; phase 2 trial in 1L mCRC in combination with standard chemotherapy planned ...